FDA issues clinical research guidance for cannabis
Benzinga reports that The FDA has now issued final guidance outlining its stand on topics relevant to scientists related to the development of human medicinal products containing cannabis or cannabis-derived compounds.
The guidance recommends:
- Sources of cannabis.
- Resources for information on quality considerations.
- Considerations of Control Status under the CSA.
The FDA has also provided recommendations for sponsors interested in developing such cannabis and cannabis-derived compounds for use in human drugs for clinical research.
Clever Leaves leaving Portugal as they let go of 21% of staff
MJ Biz Daily reports that Clever Leaves Holdings plans to cut almost one-quarter of its total workforce and wind-down operations in Portugal as part of a major restructuring effort.
The move is expected to result in USD$7 million in annualised savings.
MJ Biz Daily highlights that Clever Leaves estimates the plan will cost up to $21 million, including:
- Up to $7 million in written-off inventories.
- $12 million-$13 million in real estate and equipment exit costs.
- Almost $1 million related to severance and employee benefits.
According to the company’s statement in a U.S. Securities and Exchange Commission filing: “These savings will partially mitigate the impact of higher labour costs and headwinds from the macroeconomic environment, as well as fund additional investments to continue to drive a more efficient cost structure long term.”
Germany looks to placate brussels as its cannabis plans teeter
Delays in submitting its proposals to the European Commission and potential hold-ups once submitted could see Germany’s adult-use cannabis plans pushed back into 2025, writes BusinessCann.
Germany’s draft cannabis law will not now be submitted for Europe’s approval until the end of March.
In a statement to BusinessCann The German Federal Ministry of Health confirmed the draft law is currently ‘being formulated within the federal government’ and said it is also seeking ‘expert opinion to shed light on the effects of a controlled sale of cannabis on health and youth protection and consumption’.
It is also undertaking ‘a systematic review of the literature’ pertaining to those countries who have some form of legalised recreational cannabis, and, in a statement to BusinessCann the Home Affairs Directorate of the European Commission reiterated that personal drug consumption was a matter for nation states.